Ted M. Burns MD

Same author

Change-over in the editor position.

Muscle & nerve·2016

Same author

A newly approved drug for a rare group of diseases: Dichlorphenamide for periodic paralysis.

Neurology·2016

Same author

A new look for the journal.

Muscle & nerve·2015

Same author

Stem cell therapy in ALS: Possible benefit?

Muscle & nerve·2014

Same author

Stem cell therapy in ALS: possible benefit?

Muscle & nerve·2014

Same author

Is the "impact factor" a valid measure of the impact of research published in Clinical Neurophysiology and Muscle & Nerve?

Muscle & nerve·2012

Same journal

Characterizing Combined Central and Peripheral Demyelination-Insights From a Multimodal Comparison With Chronic Inflammatory Demyelinating Polyneuropathy and Multiple Sclerosis.

Muscle & nerve·2026

Same journal

Electrical Modalities in the Rehabilitation of Peripheral Nerve Injuries: State of the Literature and Current Clinical Applications.

Muscle & nerve·2026

Same journal

Reply to "Sural/Radial Amplitude Ratio in Non-Length-Dependent Neuropathy (NLDN): A Call for More Standardized Methodology and Further Evaluation of Distal NLDN".

Muscle & nerve·2026

Same journal

Late-Onset Myasthenia Gravis: An Increasingly Frequent Clinical Entity With Distinctive Challenges.

Muscle & nerve·2026

Same journal

Clinical Characteristics and Treatment Management of Seronegative Myasthenia Gravis: A Systematic Review of the Literature.

Muscle & nerve·2026

Same journal

Muscle-Specific Kinase Signaling and Its Therapeutic Potential.

Muscle & nerve·2026

Related Experiment Videos

Ted M. Burns MD

Related Concept Videos

Change-over in the editor position.

A newly approved drug for a rare group of diseases: Dichlorphenamide for periodic paralysis.

A new look for the journal.

Stem cell therapy in ALS: Possible benefit?

Stem cell therapy in ALS: possible benefit?

Is the "impact factor" a valid measure of the impact of research published in Clinical Neurophysiology and Muscle & Nerve?

Characterizing Combined Central and Peripheral Demyelination-Insights From a Multimodal Comparison With Chronic Inflammatory Demyelinating Polyneuropathy and Multiple Sclerosis.

Electrical Modalities in the Rehabilitation of Peripheral Nerve Injuries: State of the Literature and Current Clinical Applications.

Reply to "Sural/Radial Amplitude Ratio in Non-Length-Dependent Neuropathy (NLDN): A Call for More Standardized Methodology and Further Evaluation of Distal NLDN".

Late-Onset Myasthenia Gravis: An Increasingly Frequent Clinical Entity With Distinctive Challenges.

Clinical Characteristics and Treatment Management of Seronegative Myasthenia Gravis: A Systematic Review of the Literature.

Muscle-Specific Kinase Signaling and Its Therapeutic Potential.

Related Experiment Videos

Ted M. Burns MD

Related Concept Videos

Related Articles

Change-over in the editor position.

A newly approved drug for a rare group of diseases: Dichlorphenamide for periodic paralysis.

A new look for the journal.

Stem cell therapy in ALS: Possible benefit?

Stem cell therapy in ALS: possible benefit?

Is the "impact factor" a valid measure of the impact of research published in Clinical Neurophysiology and Muscle & Nerve?

Characterizing Combined Central and Peripheral Demyelination-Insights From a Multimodal Comparison With Chronic Inflammatory Demyelinating Polyneuropathy and Multiple Sclerosis.

Electrical Modalities in the Rehabilitation of Peripheral Nerve Injuries: State of the Literature and Current Clinical Applications.

Reply to "Sural/Radial Amplitude Ratio in Non-Length-Dependent Neuropathy (NLDN): A Call for More Standardized Methodology and Further Evaluation of Distal NLDN".

Late-Onset Myasthenia Gravis: An Increasingly Frequent Clinical Entity With Distinctive Challenges.

Clinical Characteristics and Treatment Management of Seronegative Myasthenia Gravis: A Systematic Review of the Literature.

Muscle-Specific Kinase Signaling and Its Therapeutic Potential.